These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21054260)

  • 21. The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice.
    Seminerio MJ; Hansen R; Kaushal N; Zhang HT; McCurdy CR; Matsumoto RR
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):1033-44. PubMed ID: 22932447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the necessity of translational cognitive-neurotoxicological research in methamphetamine abuse and addiction.
    Stock AK; Beste C
    Arch Toxicol; 2017 Jul; 91(7):2707-2709. PubMed ID: 28444486
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development.
    Courtney KE; Ray LA
    Prog Brain Res; 2016; 223():295-310. PubMed ID: 26806782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of sigma-1 receptor in astrocyte activation induced by methamphetamine via up-regulation of its own expression.
    Zhang Y; Lv X; Bai Y; Zhu X; Wu X; Chao J; Duan M; Buch S; Chen L; Yao H
    J Neuroinflammation; 2015 Feb; 12():29. PubMed ID: 25889537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the trace amine associated receptor 1 agonist RO5263397 on abuse-related behavioral indices of methamphetamine in rats.
    Jing L; Zhang Y; Li JX
    Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25522401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A role for sigma receptors in stimulant self-administration and addiction.
    Katz JL; Hong WC; Hiranita T; Su TP
    Behav Pharmacol; 2016 Apr; 27(2-3 Spec Issue):100-15. PubMed ID: 26650253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro.
    Kaushal N; Robson MJ; Rosen A; McCurdy CR; Matsumoto RR
    Eur J Pharmacol; 2014 Feb; 724():193-203. PubMed ID: 24380829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms underlying the involvement of the sigma-1 receptor in methamphetamine-mediated microglial polarization.
    Chao J; Zhang Y; Du L; Zhou R; Wu X; Shen K; Yao H
    Sci Rep; 2017 Sep; 7(1):11540. PubMed ID: 28912535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Physiological functions of sigma-1 receptors and its relation to psychic dependence].
    Mori T; Yoshizawa K; Shibasaki M; Suzuki T
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2012 Dec; 47(6):279-86. PubMed ID: 23461216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sigma-1 receptors: potential targets for the treatment of substance abuse.
    Robson MJ; Noorbakhsh B; Seminerio MJ; Matsumoto RR
    Curr Pharm Des; 2012; 18(7):902-19. PubMed ID: 22288407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levo-tetrahydropalmatine: A new potential medication for methamphetamine addiction and neurotoxicity.
    Liu L; Liu M; Zhao W; Zhao YL; Wang Y
    Exp Neurol; 2021 Oct; 344():113809. PubMed ID: 34256045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
    Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
    AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AC927, a σ receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells.
    Kaushal N; Elliott M; Robson MJ; Iyer AK; Rojanasakul Y; Coop A; Matsumoto RR
    Mol Pharmacol; 2012 Mar; 81(3):299-308. PubMed ID: 22101517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroimmune basis of methamphetamine toxicity.
    Loftis JM; Janowsky A
    Int Rev Neurobiol; 2014; 118():165-97. PubMed ID: 25175865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methamphetamine-, d-Amphetamine-, and p-Chloroamphetamine-Induced Neurotoxicity Differentially Effect Impulsive Responding on the Stop-Signal Task in Rats.
    Furlong TM; Leavitt LS; Keefe KA; Son JH
    Neurotox Res; 2016 May; 29(4):569-82. PubMed ID: 26846719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The methamphetamine experience: a NIDA partnership.
    Hanson GR; Rau KS; Fleckenstein AE
    Neuropharmacology; 2004; 47 Suppl 1():92-100. PubMed ID: 15464128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sigma Receptors and Substance Use Disorders.
    Sabino V; Hicks C; Cottone P
    Adv Exp Med Biol; 2017; 964():177-199. PubMed ID: 28315272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of psychostimulant addiction.
    Chen JC; Chen PC; Chiang YC
    Chang Gung Med J; 2009; 32(2):148-54. PubMed ID: 19403004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatments for methamphetamine addiction: current status and future directions.
    Ballester J; Valentine G; Sofuoglu M
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):305-314. PubMed ID: 27927042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An ethnographic exploration of self-reported violence among rural methamphetamine users.
    Sexton RL; Carlson RG; Leukefeld CG; Booth BM
    J Ethn Subst Abuse; 2009; 8(1):35-53. PubMed ID: 19266373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.